Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen

Stakeholder matrix (PDF 261 KB)

Review proposal paper (PDF 292 KB)

Prostate cancer (hormone relapsed, metastatic) - enzalutamide (after docetaxel) [ID600]: appeal announcement information

British Uro-oncology Group

British Uro-oncology Group: appeals received (PDF 321 KB)

British Uro-oncology Group: initial scrutiny letter (PDF 37 KB)

British Uro-oncology Group: response to scrutiny letter (PDF 214 KB)

British Uro-oncology Group: final scrutiny letter (PDF 17 KB)

Royal College of Physicians

Royal College of Physicians: appeals received (PDF 336 KB)

Royal College of Physicians: initial scrutiny letter (PDF 37 KB)

Royal College of Physicians: response to scrutiny letter (PDF 518 KB)

Royal College of Physicians: final scrutiny letter (PDF 19 KB)

Prostate cancer (hormone relapsed, metastatic) - enzalutamide (after docetaxel): equality impact assessment - guidance review (PDF 29 KB)

Prostate cancer (hormone relapsed, metastatic) - enzalutamide (after docetaxel): final appraisal determination information

Prostate cancer (hormone relapsed, metastatic) - enzalutamide (after docetaxel): FAD document (PDF 249 KB)

Prostate cancer (hormone relapsed, metastatic) - enzalutamide (after docetaxel): evaluation report information

Prostate cancer (hormone relapsed, metastatic) - enzalutamide (after docetaxel): evaluation report (PDF 1.56 MB)

Prostate cancer (hormone relapsed, metastatic) - enzalutamide (after docetaxel): appraisal consultation 2

Prostate cancer (hormone relapsed, metastatic) - enzalutamide (after docetaxel): appraisal consultation 2 document information

Prostate cancer (hormone relapsed, metastatic) - enzalutamide (after docetaxel): evaluation report 2 information

Prostate cancer (hormone relapsed, metastatic) - enzalutamide (after docetaxel): evaluation report 2 (PDF 746 KB)

Prostate cancer (hormone relapsed, metastatic) - enzalutamide (after docetaxel): appraisal consultation 

Prostate cancer (hormone relapsed, metastatic) - enzalutamide (after docetaxel): appraisal consultation document information

Prostate cancer (hormone relapsed, metastatic) - enzalutamide (after docetaxel): evaluation report information

Prostate cancer (hormone relapsed, metastatic) - enzalutamide (after docetaxel): evaluation report (PDF 4.6 MB)

Prostate cancer (hormone relapsed, metastatic) - enzalutamide (after docetaxel): final scope (PDF 25 KB)

Prostate cancer (hormone relapsed, metastatic) - enzalutamide (after docetaxel): final matrix (PDF 26 KB)

Prostate cancer (hormone relapsed, metastatic) - enzalutamide (after docetaxel): equality impact assessment - scoping (PDF 12 KB)

Prostate cancer (hormone relapsed, metastatic) - enzalutamide (after docetaxel): response to consultee and commentator comments on the draft scope and provisional matrix (post-referral) (PDF 70 KB)

Prostate cancer (hormone relapsed, metastatic) - enzalutamide (after docetaxel): draft scope pre-referral (PDF 106 KB)

Prostate cancer (hormone relapsed, metastatic) - enzalutamide (after docetaxel): provisional matrix pre-referral (PDF 100 KB)